GlassScriptPhysician profile
Thaslim Kassim
NPI 1518116680
$7,585.27
in general payments reported to CMS, 2019-2025
20 companies · $290 in 2025
The $290 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,330 · 2020: $114 · 2021: $175 · 2022: $2,100 · 2023: $336 · 2024: $240 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $777 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $777.32 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $4,330.18 | 2019 | |
| Abbott Laboratories | $2,157.37 | 2020-2024 | Accent, Merlin@Home |
| Actelion Pharmaceuticals US, INC. | $230.97 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Kestra Medical Technology Services, INC. | $188.97 | 2023-2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2023 | Farxiga |
| Lilly USA, LLC | $72.93 | 2022 | |
| Boston Scientific Corporation | $60.84 | 2024 | Watchman Flx |
| Amgen INC. | $60.46 | 2022-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $52.31 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.13 | 2022-2024 | Lifevest |
| Medtronic, INC. | $48.73 | 2023 | Venaseal |
| E.R. Squibb & Sons, L.L.C. | $46.04 | 2022-2025 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $32.53 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $23.45 | 2021 | |
| Inspire Medical Systems, INC. | $20.71 | 2025 | Inspire |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $19.69 | 2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $17.75 | 2024 | Xarelto |
| Pfizer INC. | $16.65 | 2021 | |
| Alnylam Pharmaceuticals INC. | $16.56 | 2023 | Amvuttra |
| Bardy Diagnostics, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaslim Kassim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.